These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Tian Y; Guo W Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491 [TBL] [Abstract][Full Text] [Related]
23. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors. Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093 [TBL] [Abstract][Full Text] [Related]
25. Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Krayem M; Najem A; Journe F; Morandini R; Sales F; Awada A; Ghanem GE Oncotarget; 2024 Jun; 15():354. PubMed ID: 38829662 [No Abstract] [Full Text] [Related]
26. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716 [TBL] [Abstract][Full Text] [Related]
27. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells. Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850 [TBL] [Abstract][Full Text] [Related]
28. NECTIN4: A Novel Therapeutic Target for Melanoma. Tanaka Y; Murata M; Shen CH; Furue M; Ito T Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478111 [TBL] [Abstract][Full Text] [Related]
29. miR-579-3p controls melanoma progression and resistance to target therapy. Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895 [TBL] [Abstract][Full Text] [Related]